Aurora Cannabis ($ACB) Stock Hub: Curaleaf’s Hostile Bid, Aurora’s Rebuttal and Q1 FY2027

01 Curaleaf’s Hostile Bid: Terms, Mechanics and Aurora’s Rebuttal

What Aurora disputes, point by point

The release is organised as a rebuttal rather than as a valuation argument. It does not respond to the price, and it does not say the offer is inadequate. What it does is attack the picture of the business that Curaleaf used to justify the price. Six claims are addressed.

Merlintrader reading: what changed on August 24, and what did not

Nothing in the economics moved. The exchange ratio, the cash component, the cap and the December 1 deadline are exactly where they were on August 19. What changed is the register: Aurora has gone from procedural language to adversarial language, has adopted the word hostile in its own headline, and has started litigating the facts in public rather than waiting for the Directors’ Circular. Read that way, the release is a preview of the arguments the Circular will make, published early to stop the bidder’s version of the business from setting in while the Special Committee works.

The part a reader should hold onto is the asymmetry in the evidence. Of the six rebuttals, one carries a specific number that can be tested later (the under-10-per-cent German reimbursement volume), one rests on a dated transaction (the UK acquisition), and the rest are assertions or non-GAAP framing that the release itself flags in a footnote. That is not unusual in a defence document. It does mean the release should be read as advocacy from the target, exactly as the bidder’s announcement should be read as advocacy from the bidder.

The market’s own reading is the more interesting number. At Curaleaf’s August 21 close of US$9.99, the package is worth roughly US$4.21 per Aurora share. Aurora closed the same day at US$3.94, about 6 per cent below. A market convinced the bid would complete on the announced terms would trade far closer to that value; a market expecting a raised bid would trade above it. Neither is happening. The discount is the price of two open questions at once: whether the Special Committee recommends against, and what the Curaleaf share component is worth by the time any take-up occurs.

Curaleaf’s August 11 proposal: an intention to bid, not a completed offer

Curaleaf Holdings announced on August 11, 2026 that it intends to make an unsolicited offer for all outstanding Aurora common shares. The legal and investment distinction matters: Curaleaf formally commenced the take-over bid on August 18, 2026, filing the offer and circular with the SEC on Schedule 14D-1F and Form F-80 and with the Canadian regulators, so Aurora shareholders can now tender. Aurora has not agreed to a transaction and, as of August 19, has filed no formal response. The consideration is 0.3463 of a Curaleaf subordinate voting share plus US$0.75 in cash per Aurora share, an implied US$4.00 based on Curaleaf’s August 10 close of US$9.39, capped at US$5.00: if the 20-day VWAP of Curaleaf shares exceeds C$17.05 at the calculation date, the share component is reset by dividing US$4.25 by that VWAP. Curaleaf puts the premium at 45 percent over Aurora’s 30-day VWAP of US$2.75 before the announcement, and 110 percent excluding Aurora’s cash. The bid carries no financing and no due-diligence condition. Curaleaf expressly states that there is no assurance the formal offer will ultimately be made or that its final terms will match the announcement.

The value is a formula, not a guaranteed US$4.00

Before any cap adjustment, the announced economics can be expressed as US$0.75 plus 0.3463 multiplied by the Curaleaf share value. A rise in Curaleaf can increase the package only up to the US$5.00 cap described by the bidder. A decline in Curaleaf would reduce the value of the stock component, and Curaleaf’s announcement did not state a floor that would preserve the US$4.00 headline value. That asymmetry is one of the most important details for ACB holders.

Curaleaf says the US$5.00 cap would represent an 82% premium to Aurora’s cited 30-day VWAP and a 197% premium on its cash-adjusted comparison. Aurora answered that the cap is a newly disclosed term and is below a price at which ACB traded as recently as December 18, 2025. The two statements are not contradictory: Curaleaf is emphasizing a premium to a recent average, while Aurora is emphasizing that the ceiling sits below a relatively recent market price.

What still has to happen before shareholders receive a real offer

Curaleaf says it will request Aurora’s shareholder list and, after receiving it, expects to file and mail a formal offer and take-over bid circular, letter of transmittal and notice of guaranteed delivery with Canadian securities regulators and the U.S. Securities and Exchange Commission. The formal circular must disclose the complete conditions, mechanics and withdrawal rights. Until those documents appear, the market is pricing an announced intention rather than an executable tender.

Curaleaf also reserved the right not to launch if it discovers previously undisclosed material adverse information, if Aurora adopts specified defensive tactics, issues shares, increases indebtedness or completes a significant transaction, or if the parties negotiate a different structure such as a plan of arrangement. Those pre-launch reservations sit alongside Curaleaf’s statement that a formally commenced offer would not be subject to financing or due diligence.

Why Curaleaf says the combination makes strategic sense

Curaleaf’s case is built around combining its U.S. and international distribution network with Aurora’s regulated global medical franchise and EU-GMP cultivation and manufacturing footprint. The bidder claims the combined group would operate across 17 countries, generate more than US$1.5 billion of last-twelve-month revenue and nearly US$350 million of last-twelve-month adjusted EBITDA, and have a pro forma market capitalization approaching US$3.0 billion. It also points to Aurora’s more than 50 tons of annual EU-GMP cultivation and manufacturing capacity, including Safari Flower Company.

Curaleaf estimates at least US$40 million of annual cost synergies from cultivation optimization, genetics deployment, vertical integration and a broader international supply chain. These are bidder projections, not audited combined-company results, not Aurora guidance and not benefits accepted by Aurora’s board. Their credibility will depend on the formal circular, integration plan, regulatory approvals and the cost required to capture them.

Aurora’s response: the board has not accepted or rejected the proposal

Aurora confirmed receiving Curaleaf letters dated June 23 and July 7. According to Aurora, only the July 7 letter contained proposed financial terms, and even that letter did not specify the cash-and-share mix later disclosed publicly. Aurora also disputed Curaleaf’s characterization that it refused to engage: the company says its lead independent director corresponded with Curaleaf CEO Boris Jordan as recently as July 24, while explaining that Aurora remained focused on executing its business plan and did not discourage continued dialogue.

Aurora’s board said it intends to form a special committee of independent directors to consider the proposal and determine a course of action in the best interests of the company and its stakeholders. The wording is precise: as of the August 11 response, the board had announced an intention to form the committee, not that the review had already produced a recommendation. Aurora said no decision has been made, the business continues to operate as usual and shareholders do not need to take any action at this time.

The next decision points

• Whether Curaleaf files and mails a formal bid on the announced terms.
• The complete offer conditions, regulatory approvals and withdrawal mechanics in the formal circular.
• The special committee’s composition, advisers, valuation work and eventual recommendation.
• Whether Aurora opens negotiations, seeks a higher price or alternative structure, or attracts another interested party.
• The trading value of Curaleaf shares, because most of the announced consideration is equity and no minimum-value floor has been disclosed.
• Whether the US$5.00 cap becomes relevant and how the final documents define the 20-day VWAP adjustment.

Q1 FY2027 remains the standalone financial base

Aurora reported first quarter fiscal 2027 results before the open on August 5, 2026, for the quarter ended June 30, 2026. Total net revenue was C$67.6 million against C$74.1 million a year earlier, down 9%. Adjusted EBITDA fell to C$3.4 million from C$10.8 million. Free cash flow was an outflow of C$5.8 million against an inflow of C$6.8 million. Cash, cash equivalents and short-term investments stood at C$149.1 million with no debt. All figures are in Canadian dollars, the company’s reporting currency.

The revenue decline is entirely composition, and it is worth splitting. Canadian medical cannabis fell 25% to C$20.7 million, because the federal reimbursement programme cut rates by roughly 30% with effect from April 1, 2026. Consumer cannabis fell from C$7.9 million to C$2.1 million, which is the deliberate wind-down. Against that, international medical cannabis grew 17% to C$43.3 million, driven by German patient demand, and is now the largest single line in the business. The company is shrinking where policy and choice say it should, and growing where it says the future is.

One line needs reading twice. Gross profit rose to C$35.6 million from C$33.5 million, which reads as an improvement. It is not an operating one: it includes a C$12.6 million larger gain on the change in fair value of biological assets, a non-cash accounting item tied to growing plants. Gross profit before fair-value adjustments fell from C$38.8 million to C$29.2 million, and the adjusted gross margin before fair-value adjustments went from 64% to 58%, and from 69% to 61% on medical revenue alone. The reimbursement cut lands squarely on margin, and the headline gross profit line hides it. The same fair-value gain flatters the net loss, which narrowed to C$4.0 million from C$10.2 million.

Costs held: adjusted selling, general and administrative expense was C$35.1 million against C$36.1 million. Adjusted net income was C$3.8 million against C$6.6 million. Guidance for fiscal 2027 was left unchanged, and management said it expects both revenue and adjusted EBITDA to be sequentially higher in the second quarter. That sequential improvement, not the year-on-year comparison, is the thing to check when Q2 FY2027 is reported; Aurora had not announced the reporting date as of August 11.

Aurora’s most important post-July 12 operating development is the July 23 confirmation that Safari Flower Company received a three-year EU-GMP certification for its 59,000 square foot Ontario facility. The certification preserves the facility’s ability to supply tightly regulated international medical markets and supports Aurora’s planned export network for Germany, Poland and the UK.

Safari closed on April 14, 2026 and Aurora intends to invest about C$3.5 million over three years in growth capital at the facility. The quarter reported on August 5 is the first to carry the Canadian medical reimbursement reset of April 1, the consumer wind-down and the early Safari integration, and all three are visible in the numbers above.

Aurora’s virtual annual meeting was held on August 7. ISS had recommended votes in favour of all director nominees and meeting resolutions. As of August 9, Aurora had not posted a standalone official release with the final voting results; the meeting therefore does not change the operating thesis in this update.

Capital watch: the balance sheet remains comparatively strong, but the US$100 million ATM, negative FY2026 free cash flow and Aurora’s dilution history remain relevant. Safari’s certification lowers regulatory execution risk; it does not yet prove utilization, export volume, margin improvement or per-share value creation.

Static Finviz chart for ACB. The chart is provided as a visual reference only and does not represent investment advice.

Stock Hub · Cannabis · Medical Cannabis
Aurora Cannabis ($ACB) Stock Hub: Curaleaf’s Unsolicited Takeover Proposal and Q1 FY2027

Aurora Cannabis is no longer best understood as a legacy Canadian recreational cannabis story. The current thesis is built around global medical cannabis, EU-GMP manufacturing, Germany, Poland, Australia, New Zealand, balance sheet discipline, and the difficult transition away from lower-margin consumer cannabis.

Updated: August 18, 2026
Ticker: Nasdaq / TSX: ACB
Company: Aurora Cannabis Inc.
Focus: Global Medical Cannabis

02 Executive Summary

Aurora Cannabis enters the second half of calendar 2026 as one of the cleaner but still highly debated names in the listed cannabis sector. The company has moved away from the old Canadian recreational cannabis growth story and is now trying to prove that a regulated, medical-first, international cannabis platform can generate more durable margins than the sector’s legacy consumer model.

The August 11 Curaleaf announcement changes the near-term framing. ACB is now both a standalone global medical cannabis execution story and an event-driven takeover candidate. Curaleaf’s stated US$4.00 value is made up of 0.3463 Curaleaf shares plus US$0.75 cash, is capped at US$5.00 if Curaleaf rises and has no disclosed minimum-value floor. The offer was formally commenced on August 18, 2026 and runs to December 1, 2026 unless extended.

Aurora answered that its board intends to form a special committee of independent directors. It has neither accepted nor rejected the proposal, says shareholders need take no action and will continue operating the business while the review develops.

Aurora’s August 5 Q1 FY2027 report is now the latest quarterly financial base. Total net revenue fell 9% year over year to C$67.6 million, adjusted EBITDA declined to C$3.4 million and free cash flow was an outflow of C$5.8 million, while international medical revenue grew 17% to C$43.3 million. FY2026 remains the annual benchmark, with record global medical cannabis net revenue of C$288.6 million and record adjusted EBITDA of C$53.8 million.

The operating picture advanced across late July and early August. On July 23, Safari Flower Company received a three-year EU-GMP certification for its 59,000 square foot Ontario facility. The August 5 Q1 report then showed the first financial effects of the April 1 Canadian medical reimbursement reset, the consumer wind-down and early Safari integration: Canadian medical revenue fell 25%, consumer revenue fell to C$2.1 million and international medical revenue grew 17%. Management left FY2027 guidance unchanged and expects Q2 revenue and adjusted EBITDA to improve sequentially.

That is the constructive side of the story. Aurora is not simply burning cash and waiting for U.S. legalization. It has built a meaningful medical cannabis revenue base, with international medical revenue of C$176.5 million in fiscal 2026, up from C$137.0 million in fiscal 2025. In Q4 FY2026, international medical cannabis revenue reached C$48.8 million, supported by higher sales in Europe, mainly Germany, and growth in Poland.

But the story is not one-dimensional. Q4 was weaker than the full-year headline suggests. Adjusted EBITDA fell to C$9.2 million in Q4 FY2026 from C$18.4 million in Q3 FY2026 and C$14.1 million in Q4 FY2025. Free cash flow was only C$0.3 million in Q4, and full-year free cash flow was negative C$14.3 million, versus positive C$10.9 million in fiscal 2025. Aurora also guided fiscal 2027 toward a reset year, with total net revenue expected to decline and adjusted EBITDA expected to be lower than fiscal 2026 because of Canadian medical reimbursement pricing revisions.

That tension is exactly why $ACB remains interesting. The company is cleaner than it used to be, more medical-focused than most cannabis names, and less dependent on the broken Canadian recreational model. At the same time, the stock still carries the scars of the old cannabis cycle: dilution history, sector skepticism, regulatory volatility, price compression, weak retail trust, and the constant need to separate adjusted profitability from IFRS net losses.

The central question for Aurora is no longer whether cannabis can become a hype sector again. The real question is whether Aurora can become a serious, regulated, medical cannabis export and manufacturing platform with enough margin, cash discipline, and international growth to deserve a valuation outside the cannabis graveyard.

03 Curaleaf Proposal and August 2026 Developments: What Actually Changed

Curaleaf takes an unsolicited proposal public, then commences the bid

On August 11, Curaleaf announced its intention to launch a cash-and-stock offer for Aurora after private letters dated June 23 and July 7. Aurora responded the same afternoon, disputed that it had refused dialogue and said its lead independent director had corresponded with Curaleaf as recently as July 24. The board intends to form an independent special committee; no recommendation has been made.

The immediate analytical change is not that Aurora has been sold. It is that ACB now carries a live strategic-process overlay whose value depends on formal commencement, the Curaleaf share price, the complete conditions and Aurora’s response.

Safari receives a three-year EU-GMP certification

On July 23, 2026, Aurora announced that Safari Flower Company’s Niagara Region facility had received EU-GMP certification for a three-year term. The 59,000 square foot cultivation and manufacturing site was acquired in April to add export-capable capacity and reduce reliance on third-party purchases. Aurora specifically identified Germany, Poland and the UK among the markets Safari is intended to support.

This is strategically meaningful because the acquisition thesis depended on regulated international access. The certification lowers one important integration and compliance risk. It does not, by itself, prove production utilization, export volume, cost savings or margin accretion. Those outcomes must now appear in the financial statements.

Q1 FY2027 confirms the reimbursement and margin reset

Aurora reported Q1 FY2027 on August 5. Total net revenue fell 9% to C$67.6 million and adjusted EBITDA declined to C$3.4 million, while international medical revenue rose 17% to C$43.3 million. Canadian medical revenue fell 25% after the April 1 reimbursement change, adjusted gross margin before fair-value adjustments narrowed to 58%, and free cash flow was an outflow of C$5.8 million. Management kept FY2027 guidance unchanged and expects sequentially higher Q2 revenue and adjusted EBITDA.

AGM results confirm the five-member board that now faces the proposal

Aurora filed the final voting results on August 10. Shareholders approved a five-director board with 91.65% support, elected all five nominees with approximately 85.1% to 86.5% of votes cast in favour, approved Ernst & Young with 92.81% support and backed the advisory say-on-pay resolution with 82.97%. About 26.86% of outstanding shares were represented. The result did not alter the operating outlook, but it confirms the board whose independent members must now evaluate Curaleaf’s proposal.

04 Quick Snapshot

Q1 FY2027 Net Revenue
C$67.6M
Down 9% from C$74.1M. International medical up 17% to C$43.3M.
Q1 FY2027 Adjusted EBITDA
C$3.4M
From C$10.8M. Free cash flow an outflow of C$5.8M.
FY2026 Total Net Revenue
C$320.6M
Compared with C$288.9M in FY2025.
FY2026 Medical Cannabis Revenue
C$288.6M
Record annual global medical cannabis net revenue.
FY2026 Adjusted EBITDA
C$53.8M
Up 32% year over year.
Cash / Restricted Cash / Short-Term Investments
C$149.1M
At June 30, 2026, against ~C$164.7M at March 31, 2026.
Conventional Debt
None
Aurora reported no debt at June 30, 2026.
Next Major Watch Item
Q2 FY2027
Reporting date not announced as of August 11; management expects sequentially higher revenue and adjusted EBITDA.

05 Why Aurora Matters Now

Aurora matters now because the company is trying to do something different from the cannabis sector’s failed 2018–2021 playbook.

The old cannabis thesis was built on huge Canadian cultivation capacity, recreational legalization, retail brand expansion, international optionality, and the assumption that large licensed producers would eventually dominate an enormous consumer market. That story mostly broke. Canada became oversupplied, price competition intensified, consumer cannabis margins disappointed, and the capital structures of many cannabis companies became a long-term burden.

Aurora’s current model is much narrower and more disciplined. The company is focusing on medical cannabis, regulated international markets, pharmaceutical-grade manufacturing, EU-GMP certification, proprietary genetics, and direct or indirect access to pharmacy-based medical channels. In other words, Aurora is trying to become less like a consumer packaged goods cannabis stock and more like a specialized medical cannabis supplier.

That is not just a marketing distinction. In FY2026, medical cannabis represented the overwhelming majority of Aurora’s continuing net revenue. In Q4 FY2026, medical cannabis net revenue of C$77.1 million represented 91% of consolidated Q4 net revenue and generated more than 100% of adjusted gross profit before fair value adjustments, because consumer and wholesale bulk cannabis were much weaker contributors.

The medical segment also carries much stronger economics than the consumer business. For fiscal 2026, Aurora reported adjusted gross margin before fair value adjustments of 68% for medical cannabis, compared with 28% for consumer cannabis and only 3% for wholesale bulk cannabis.

Core positive read

Aurora has become a medical cannabis platform first. That gives the company a cleaner operating identity than many legacy cannabis peers and helps explain why gross margin, international growth and regulatory execution matter more than Canadian recreational market share.

That margin gap explains the whole strategic pivot. Aurora is not winding down lower-margin consumer exposure because it has no brands. It is doing so because the medical business is where the company believes the return on capital is higher.

The market’s problem is that this cleaner strategy comes with a reset. Fiscal 2026 proved that Aurora can generate record medical revenue and record adjusted EBITDA. Fiscal 2027 now has to prove that this model can absorb Canadian pricing pressure, maintain international growth, integrate Safari Flower, complete the consumer wind-down, and still protect cash.

06 The New Aurora: Medical Cannabis First, Not U.S. Legalization First

The most important correction to the old Aurora narrative is that $ACB is not primarily a U.S. legalization trade today.

Aurora’s annual disclosure states that the company does not currently have direct or indirect cannabis investments in the United States. The company also says any future U.S. market strategy must consider state and federal rules and that it is committed to only engaging in activities permissible under both state and federal laws.

That matters because many cannabis stocks still trade around U.S. reform headlines, even when the operating exposure is elsewhere. Aurora may benefit from improved U.S. cannabis sentiment if federal reform, rescheduling, or medical frameworks improve investor appetite for the sector. But the company’s actual business engine is not U.S. plant-touching exposure. The operational engine is Canada plus international medical cannabis, especially Europe and Australia.

This makes Aurora a different kind of cannabis watchlist name. It is not the cleanest way to play U.S. multi-state operator upside. It is not a pure Canadian consumer cannabis story. It is a global medical cannabis execution story.

The company’s FY2026 Annual Information Form describes Germany as one of the largest federally legal medical cannabis markets outside Canada and notes that Germany continues to rely on imports to meet growing demand. Aurora says its German subsidiary has held relevant licenses and permits and has been importing, exporting, and distributing medical cannabis within the European Union since Germany legalized its medical market. The company also says it is one of the top importers and distributors of medical cannabis in Germany and one of only three companies actively producing medical cannabis within Germany.

That German footprint is central to the story. Aurora is not simply exporting opportunistically. It has regulatory infrastructure, distribution, EU-GMP manufacturing capacity, and an existing operating base in the German market.

07 The FY2026 Numbers: Strong Full Year, Messier Q4

Aurora’s FY2026 report contains two stories at once.

The first story is strong. Full-year total net revenue increased to C$320.6 million, up from C$288.9 million in FY2025. Global medical cannabis net revenue increased to C$288.6 million, up from C$244.4 million. Adjusted EBITDA increased to C$53.8 million, up from C$40.9 million. Adjusted net income increased to C$39.3 million, up from C$27.2 million.

The second story is more complicated. Net loss from continuing operations was C$58.6 million in FY2026, compared with net income from continuing operations of C$27.1 million in FY2025. Total net loss was C$136.0 million, driven in part by discontinued operations, impairment, fair value movements, business transformation costs, and the Bevo-related reset.

Important accounting note

Aurora cannot be analyzed only through the adjusted EBITDA headline. The adjusted numbers show the cleaner operating direction. The IFRS numbers show the real accounting noise, restructuring cost, impairment risk, and legacy complexity that still exists.

FY2026 Revenue Breakdown

The table tells the story. Medical cannabis is rising, international medical is rising faster, consumer cannabis is shrinking, and wholesale bulk cannabis is not the strategic core.

Q4 FY2026: The Warning Inside the Record Year

Q4 FY2026 was not a clean acceleration quarter. Total net revenue was C$84.8 million, up 10% year over year and up 2% sequentially. Medical cannabis net revenue was C$77.1 million, up 14% year over year but only 1% sequentially. Consumer cannabis net revenue fell to C$3.6 million, down 55% year over year.

Adjusted EBITDA fell to C$9.2 million, down 50% sequentially and down 34% year over year. Adjusted net income fell to C$5.6 million, down 52% sequentially and down 63% year over year. Free cash flow was only C$0.3 million, down sharply from C$18.6 million in Q3 FY2026 and C$5.2 million in Q4 FY2025.

This does not destroy the Aurora story, but it changes the tone. The company’s full-year results confirm a real medical cannabis platform. The Q4 trend and FY2027 guidance tell investors not to extrapolate FY2026 adjusted EBITDA in a straight line.

08 The FY2027 Reset

The most important part of the June 2026 update may not be FY2026 itself. It may be management’s FY2027 outlook.

Aurora said fiscal 2027 total net revenue is expected to decline and be more in line with fiscal 2025 cannabis net revenue, after changes in Canadian medical reimbursement, partially offset by international growth driven by Germany and Poland. The company also guided adjusted gross margin before fair value adjustments to the mid-to-high fifties and said adjusted SG&A should remain broadly in line with the prior year. Most importantly, adjusted EBITDA is expected to be lower than fiscal 2026 because revised reimbursed pricing is expected to pressure net revenue and adjusted gross profit.

This is a major framing point. Aurora’s medical strategy is credible, but FY2027 is not being guided as a simple continuation of FY2026 growth. The company is effectively saying that the portfolio will be cleaner after exiting lower-margin businesses, but the near-term financial optics will be pressured by reimbursement changes and business transition.

Key risk for FY2027

The reset is not cosmetic. Management is explicitly guiding lower annual adjusted EBITDA versus FY2026. The stock needs evidence that this is a transitional year, not the start of renewed margin compression in medical cannabis.

For a stock hub, this is the dividing line. The bull case is not “FY2026 was good, therefore FY2027 will automatically be better.” The bull case is that FY2027 may be a reset year, but the reset could leave Aurora more focused, more medical, more international, and better positioned for FY2028. The bear case is that FY2026 was the high-water mark and FY2027 may reveal that medical cannabis pricing and reimbursement are less durable than the market hoped.

09 Business Model

Aurora’s current business can be simplified into three buckets: global medical cannabis, limited residual consumer cannabis exposure, and residual economic exposure to plant propagation after the Bevo transaction.

1. Global Medical Cannabis

This is the core business.

Aurora serves medical markets in Canada, Europe, Australia and New Zealand, with brands that include Aurora, MedReleaf, Pedanios, IndiMed, San Rafael and Whistler Medical Marijuana Corporation. Medical cannabis includes flower, extracts, oils, cartridges, and other patient-focused products depending on the market.

The key difference from recreational cannabis is the channel: physician involvement, pharmacy distribution, reimbursement structures in some markets, stricter product standards, and higher regulatory barriers.

This is why Aurora’s EU-GMP and TGA-GMP capabilities matter. International medical cannabis is not just a commodity flower export market. Regulated medical markets generally require documentation, quality systems, batch consistency, import/export licensing, and compliance with pharmaceutical-grade standards.

2. Limited Consumer Cannabis

Aurora still reported consumer cannabis revenue in FY2026, but this is no longer the center of the story. The company is winding down certain lower-margin Canadian consumer cannabis markets and says it expects to have very limited activity in the Canadian consumer market, with a full wind-down in the coming months.

Consumer cannabis net revenue fell from C$40.0 million in FY2025 to C$23.5 million in FY2026. In Q4 FY2026, consumer cannabis net revenue was only C$3.6 million, compared with C$8.2 million in Q4 FY2025.

The consumer exit reduces near-term revenue, but it may improve business quality if Aurora can redeploy capacity and resources toward medical markets with better margins.

3. Plant Propagation Residual Exposure

Aurora’s plant propagation business is no longer consolidated after the Bevo transaction closed on February 17, 2026. Aurora exchanged its 50.1% ownership interest in Bevo for preferred shares and retained certain financial rights, including a 5% annual dividend on the par value of the preferred shares, distributions tied to eligible Bevo cash flow, and earnout rights connected to the Aurora Sky and Aurora Sun facilities.

This is important because it simplifies Aurora’s reported business but does not eliminate all residual exposure. The company still has economic interests tied to Bevo’s future performance, and its Annual Information Form warns that the realizable value of those preferred shares and earnout entitlements depends on factors outside Aurora’s control.

The market may like the simplification, but investors still need to watch the residual Bevo exposure.

10 Medical Cannabis: The Core Economic Engine

The strongest part of Aurora’s report is the medical cannabis segment.

For fiscal 2026, medical cannabis net revenue was C$288.6 million, representing roughly 90% of total net revenue. Medical cannabis adjusted gross margin before fair value adjustments was 68% for the year. In Q4, medical cannabis adjusted gross margin was 66%, down from 69% in Q3 and 71% in the prior-year quarter.

That margin remains high, but the direction matters. The company said Q4 medical cannabis margin pressure was affected by product sales mix, third-party sourcing, and strategic price reductions to preserve market share amid increased competition.

Margin watch

High-margin medical cannabis is the reason Aurora is investable as a differentiated cannabis story. If competition forces sustained price reductions, the valuation thesis becomes less powerful. If the company can maintain margins in the mid-to-high fifties or better while growing international revenue, the thesis remains alive.

Medical cannabis is therefore both the upside engine and the risk center.

11 International Growth: Germany and Poland Lead the Story

International medical cannabis is the strongest growth engine in Aurora’s portfolio.

International medical cannabis net revenue increased from C$137.0 million in FY2025 to C$176.5 million in FY2026. In Q4 FY2026, international medical cannabis net revenue was C$48.8 million, compared with C$41.0 million in Q4 FY2025. Aurora attributed the year-over-year Q4 increase mainly to higher sales in Poland and Germany, driven by increased patient demand.

Germany is the most important market in this discussion. Aurora describes Germany as one of the largest federally legal medical cannabis markets outside Canada and says the country continues to rely on imported medical cannabis to meet demand. The company also highlights that Germany’s medical cannabis market received a major boost from the 2024 descheduling of medical cannabis.

Aurora’s German business is not theoretical. The company acquired Aurora Germany in 2017, and that subsidiary has been importing, exporting, and distributing medical cannabis in the European Union since German medical legalization. Aurora also says it distributes directly to German pharmacies and indirectly through wholesalers and pharmacies.

Poland is the other major growth marker. Aurora’s FY2026 Annual Information Form notes the launch of proprietary cultivars Farm Gas and Sourdough in Poland in June 2025 and Black Jelly in December 2025, describing Poland as one of Europe’s fastest-growing medical cannabis markets.

The international story is not only about demand. It is about regulated supply. The winners in medical cannabis are not necessarily the companies with the most cultivation capacity. They are the companies that can deliver consistent, certified, compliant product into markets where doctors, pharmacies, regulators, importers, and patients care about reliability.

That is the lane Aurora is trying to occupy.

August 19, 2026 — the United Kingdom is added to the owned supply chain. Aurora acquired 100 per cent of Internode Pharma Limited, a licensed importer and wholesaler, and HAP Pharma Limited, a licensed pharmacy, through a wholly owned subsidiary, paying selling shareholders GBP 2.1 million in cash at closing, contingent on the satisfaction of certain post-closing conditions. The two companies run a licensed import and distribution facility and a virtual pharmacy in Birmingham, which gives Aurora direct control of the chain from cultivation to patient delivery in a market of roughly 70 million people. The company expects the transaction to be accretive to adjusted EBITDA in future quarters through operational efficiency and reduced reliance on third-party distributors, and says it will look at further investment in UK distribution capacity. The amount involved is small next to the Curaleaf bid, but it tells you where management is putting money while the takeover plays out. (Source: Form 6-K, Exhibit 99.1, August 19, 2026)

12 Germany: Big Opportunity, Real Regulatory Risk

Germany is both Aurora’s biggest opportunity and one of its clearest regulatory risks.

The opportunity is straightforward. Germany is large, federally legal for medical cannabis, import-dependent, and pharmacy-based. Aurora has licenses, distribution, EU-GMP infrastructure, and domestic production exposure in Germany.

The risk is that Germany’s medical cannabis boom has attracted regulatory scrutiny. Any tightening around telemedicine prescriptions, online access, pharmacy distribution, advertising, reimbursement, or import requirements could affect the pace and quality of growth.

For Aurora, this is nuanced. A crackdown on low-friction online prescription models could slow some demand growth and pressure near-term volumes. But it could also favor companies with stronger regulated medical infrastructure, pharmacy relationships, EU-GMP supply, and a more pharmaceutical-style operating model.

Aurora’s own positioning appears aligned with the more formal medical model. The company emphasizes regulatory expertise, EU-GMP supply, pharmacy distribution, and medical channel execution. If Germany moves toward a stricter prescription-and-pharmacy framework, the result may be negative for some online-first demand channels but not necessarily fatal for Aurora’s long-term position.

The key question is whether the market’s growth rate remains strong enough after tighter rules. If Germany becomes more regulated but still expands, Aurora may benefit from quality barriers. If Germany slows materially or reimbursed prices decline, the bull case weakens.

13 Australia and New Zealand: Growth Market With Competitive Pressure

Australia is another important market, but the signal is mixed.

Aurora has a meaningful presence through MedReleaf Australia and product expansion across medical cannabis formats. In December 2025, Aurora announced that MedReleaf Australia had entered a distribution partnership with Leafio, the wholesale distribution arm of Montu Australia, to expand patient access to Aurora’s medical cannabis products and support healthcare professionals.

In February 2026, Aurora also advanced its medical growth strategy with portfolio expansion in Australia and New Zealand, including new THC flower products, a balanced THC/CBD product, and resin cartridges.

But Australia is not frictionless. Aurora’s Annual Information Form warns that the Australian medical cannabis market has experienced a rapid increase in licensed importers, distributors and competing brands, creating pricing pressure. The company recognized a non-cash impairment charge of approximately C$13.2 million against intangible assets allocated to its Australian cannabis cash-generating unit during FY2026.

Australia read-through

Australia is a growth market, but not a guaranteed margin expansion market. Aurora can grow there, but it must defend pricing, brand relevance, physician trust, and channel access in a more competitive environment.

14 Safari Flower Company: EU-GMP Certification Moves the Deal Into Execution

Aurora’s April 2026 acquisition of Safari Flower Company remains one of the most important post-FY2026 strategic events, and the July 23 certification announcement materially advances the integration thesis.

Aurora acquired Safari for total consideration of C$26.5 million, subject to customary adjustments. The consideration included C$15 million in cash and 2,417,180 common shares valued at approximately C$11.5 million, plus C$2 million of contingent consideration tied to satisfying certain GMP certifications.

Safari’s Niagara Region facility is a 59,000 square foot cultivation and manufacturing site. On July 23, Aurora announced that the facility had received EU-GMP certification for a three-year term, reinforcing its ability to supply regulated international medical cannabis markets. Aurora identified Germany, Poland and the UK as target markets supported by this capacity.

This is more than a ceremonial milestone. Aurora’s acquisition rationale was to add export-capable EU-GMP capacity, support international demand and reduce reliance on third-party purchases. The certification removes a meaningful regulatory uncertainty and makes the facility more directly usable inside Aurora’s global manufacturing and export network.

Certification is not the same as economic proof

The July 23 release did not quantify expected shipments, facility utilization, cost savings or gross-margin contribution. It also did not state whether this specific certification satisfies all or part of the C$2 million contingent-payment condition. Investors should therefore avoid treating the certification as immediate evidence of accretion.

The next evidence must come through production volumes, export sales, lower third-party sourcing, medical gross-margin resilience and cash conversion. If Safari becomes a reliable supplier to Germany, Poland and the UK without adding excessive working-capital or integration costs, it can become a meaningful FY2027/FY2028 asset. If utilization is slow, the deal will remain strategically logical but financially unproven.

15 Germany Facility Upgrades and EU-GMP Infrastructure

Aurora’s European infrastructure is another key part of the story.

The FY2026 Annual Information Form states that Aurora undertook an expansion project at its Leuna, Germany facility during fiscal 2026 to drive more EU-GMP production capacity. The company says the improvements are expected to increase flower growth capacity, improve product quality, and drive cost efficiency.

Aurora expects the project to be completed in the first half of fiscal 2027 and, combined with proprietary cultivars, to double the site’s annual flower output. This is one of the most concrete FY2027 operational catalysts.

If the Leuna upgrades are completed successfully, Aurora can strengthen its local European manufacturing base. That could matter for Germany, broader EU supply, cost control, and regulatory credibility.

However, this is also a capital allocation test. Aurora’s cash flow statement shows increased investing cash use in FY2026 partly related to short-term investments and property, plant and equipment purchases, including Leuna upgrades.

The market will want to see whether this investment produces real revenue, better margins, and lower reliance on third parties, not just higher capital intensity.

16 Science, Genetics and IP: A Less Obvious Differentiator

Aurora is also trying to build differentiation through genetics and plant science.

The company’s FY2026 Annual Information Form notes progress in powdery mildew resistance research. Aurora says it identified a novel source of genetic resistance known as PM2 and performed multiple rounds of crosses to transfer that resistance into elite breeding lines. If production trials are successful, Aurora expects to commercialize PM-resistant cultivars, potentially protecting plant health, reducing operating costs and improving product quality.

Aurora also secured EU Community Plant Variety Rights for two proprietary cannabis varieties during fiscal 2026, strengthening the company’s intellectual property portfolio around proprietary cultivars.

This is not the kind of catalyst retail traders usually chase, but it matters in a medical cannabis model. If Aurora can improve yields, disease resistance, consistency, potency, and product quality through proprietary genetics, the result could be stronger margins and better supply reliability.

The risk is that IP and genetics are hard for the market to value. They sound good, but the market will ultimately want evidence in gross margin, cultivation cost, yield, product demand, and international sell-through.

17 Balance Sheet

Aurora’s balance sheet is one of the better parts of the story.

The phrase “no debt” used in Aurora’s release should be read carefully. Aurora had no conventional loans and borrowings at fiscal year-end, but it still had lease liabilities and other obligations. That distinction matters for conservative readers. The balance sheet is strong relative to many cannabis peers, but “no debt” does not mean “no obligations.”

The balance sheet also gives Aurora flexibility. The company can fund operations, capacity expansion, and selective acquisitions without immediate financial distress. But the negative FY2026 free cash flow and the FY2027 EBITDA reset mean investors should still monitor cash conversion closely.

18 Dilution and Share Count

Aurora has a long history of dilution, reverse splits, and capital structure pain. That history is one reason the market still discounts the name heavily.

As of March 31, 2026, Aurora had 58,947,593 common shares outstanding. During FY2026, the company issued 2,210,785 shares through equity financing and received C$10.9 million of proceeds from share issuance, with C$1.6 million of share issuance costs.

On February 4, 2026, Aurora filed a prospectus supplement establishing an at-the-market program allowing the company to issue and sell up to US$100 million of common shares from treasury. The company said proceeds would be used only for strategic and accretive purposes, including cultivation capacity and potential M&A.

After fiscal year-end, the Safari acquisition added 2,417,180 common shares as part of the consideration.

Dilution remains a watch item

The key question is not whether Aurora can issue stock. It can. The key question is whether any issuance is genuinely accretive and tied to capacity, revenue, margin, or strategic positioning. For a company still heavily discounted by cannabis-sector history, equity issuance at depressed prices can become painful quickly.

19 Free Cash Flow: The Metric That Matters Most

Adjusted EBITDA is useful, but free cash flow is more important.

Aurora reported adjusted EBITDA of C$53.8 million in FY2026, but free cash flow was negative C$14.3 million. In Q4, adjusted EBITDA was C$9.2 million, while free cash flow was only C$0.3 million.

This gap is not automatically alarming because FY2026 included restructuring, working capital investment, capex and transition costs. But it prevents the story from being too clean.

The market will likely reward Aurora only if adjusted EBITDA increasingly converts into cash. For FY2027, that may be difficult because the company is guiding lower adjusted EBITDA and still digesting the consumer exit, reimbursement changes, Safari integration, and capacity investments.

What a cleaner Aurora bull case needs

• Medical cannabis revenue remains resilient.
• Gross margins stabilize above the mid-to-high fifties.
• Free cash flow returns to positive territory without aggressive dilution.

Until that happens, the stock remains a reset story rather than a fully proven compounder.

20 Management and Governance

Aurora is led by Executive Chairman and CEO Miguel Martin and CFO Simona King. Martin’s current strategic message is consistent: Aurora is focused on global medical cannabis, regulatory expertise, EU-GMP supply, and disciplined execution. In the FY2026 release, he stated that the company exceeded its projection for global medical cannabis net revenue and delivered record adjusted EBITDA, validating the global medical cannabis strategy.

Governance deserves a balanced view.

On one hand, Aurora has simplified the business, exited or de-emphasized weaker segments, divested Bevo control, focused on medical cannabis, and maintained a stronger balance sheet than many cannabis peers. Final AGM results filed August 10 show that all five directors were elected with approximately 85.1% to 86.5% support, the auditor appointment passed with 92.81% and say-on-pay passed with 82.97%.

The August 11 proposal now creates a direct governance test. Aurora’s board intends to form a special committee of independent directors to assess Curaleaf’s terms, standalone value and other strategic alternatives. Investors should distinguish that announced review process from a board recommendation: no decision has been made, and Aurora has not accepted or rejected the proposal.

The more important governance tests are now the independence and transparency of the strategic review, disciplined capital allocation during the process, restrained ATM usage and credible remediation of the internal-control weakness.

On the other hand, the FY2026 annual report includes an adverse opinion on internal control over financial reporting. Ernst & Young stated that Aurora did not maintain effective internal control over financial reporting as of March 31, 2026 because of a material weakness related to controls over the completeness and accuracy of inputs to significant estimates, assumptions and formulas in certain significant accounts. The auditor also stated that this material weakness did not affect its unqualified opinion on the FY2026 consolidated financial statements.

Governance watch

Cannabis accounting already involves biological assets, fair value assumptions, impairment testing, inventory estimates, and complex international operations. A material weakness in controls over significant estimates is a governance and reporting red flag, even if the audited financial statements received an unqualified opinion.

The correct framing is simple: management has improved strategic focus, but internal control remediation should remain on the watchlist.

21 Market Setup

ACB remains a damaged cannabis-sector equity. The stock trades far below historical cannabis mania levels and remains under the heavy shadow of prior dilution, reverse splits, sector disappointments and weak retail trust.

That price action reflects two things at once. Cannabis stocks remain out of favor, and the market is not yet willing to pay a premium for Aurora’s medical cannabis reset.

From a watchlist perspective, Q1 delivered mixed evidence: international medical revenue grew 17%, but Canadian medical pricing pressure, weaker adjusted margins, lower adjusted EBITDA and negative free cash flow kept the FY2027 reset intact. The next proof is whether Q2 revenue and adjusted EBITDA improve sequentially while Germany, Poland and Safari support the mix without excessive cost or ATM dilution.

The setup is now both event-driven and operational. Curaleaf’s announcement creates a discrete strategic path, but it is not yet a binding agreement or formally open tender. ACB can trade with the probability of formal commencement, Curaleaf’s share price, the committee’s response and possible alternatives while the standalone value continues to depend on quarterly revenue mix, international sales, margin stability, ATM activity and cash flow.

22 Retail Sentiment

The Stocktwits reading below was captured on August 9, 2026, before Curaleaf announced its intention to bid. It is kept as a dated pre-event baseline and should not be read as the retail reaction to the takeover headline, which arrived on August 11 and again on August 19 and August 24.

Retail sentiment around Aurora remains mixed. The company has a better story than many cannabis names, but trust in the sector is still low after years of capital destruction.

On social platforms such as Reddit, Stocktwits and X, Aurora is often discussed through two conflicting lenses. The positive camp focuses on medical cannabis revenue, international growth, Germany, the balance sheet, Safari capacity and the consumer exit. The skeptical camp focuses on dilution history, falling Q4 EBITDA, FY2027 guidance, negative free cash flow, and the broader failure of the listed cannabis sector to sustain past rallies.

This matters because Aurora does not only need operational improvement. It also needs the market to believe that this version of the company is structurally different from the old cannabis bubble version.

23 Key Catalysts to Watch

1. The Directors’ Circular and the Special Committee recommendation

The bid is open and the intention stage is over: Curaleaf commenced the offer on August 18, 2026 and it runs to at least December 1, 2026. The next hard document is therefore Aurora’s side, not Curaleaf’s. Aurora has said shareholders will be notified of the Board’s formal recommendation through a news release and a Directors’ Circular; as of August 24, 2026 neither had appeared, and the August 24 rebuttal release states explicitly that the Special Committee has not yet made a formal recommendation. A recommendation against, a recommendation in favour, or the emergence of a competing bidder are three very different outcomes for the shares, and the Circular is where one of them becomes official.

2. Aurora Special Committee and Board Recommendation

Aurora’s board intends to form a special committee of independent directors. Investors should watch for the committee’s composition, financial and legal advisers, any formal valuation, the board’s recommendation and whether Aurora seeks a higher price, a negotiated plan of arrangement or another strategic alternative. Aurora has told shareholders that no action is required now.

3. Curaleaf Share Price and the Floating Offer Value

The announced package is US$0.75 cash plus 0.3463 Curaleaf shares. Its value therefore changes with Curaleaf until the stated US$5.00 cap is triggered and the share count is adjusted. No minimum-value floor was disclosed, so a decline in Curaleaf can reduce the package below the US$4.00 headline value.

4. Competing Interest or a Negotiated Alternative

Curaleaf’s public move establishes that a strategic buyer assigns value to Aurora’s international medical platform and EU-GMP capacity. That does not prove another bidder exists, but Aurora’s committee can compare the proposal with standalone value and other alternatives. Any higher proposal, negotiated transaction or rejection would materially change the event path.

5. Q2 FY2027 Sequential Improvement · Reporting Date Not Announced

Management expects both revenue and adjusted EBITDA to improve sequentially in Q2, but Aurora had not announced the reporting date as of August 11. The standalone value case still depends on international medical growth, the Canadian reimbursement effect, adjusted gross margin, free cash flow, Safari integration and any ATM usage or change to full-year guidance.

6. Safari Commercialization After EU-GMP Certification

The regulatory milestone is complete for a three-year term. The next questions are commercial: how quickly Safari contributes export volume, whether it reduces third-party sourcing, what utilization looks like, and whether the acquired capacity improves medical margins without creating working-capital pressure.

7. Germany and Poland Growth

Aurora’s international medical growth depends heavily on Germany and Poland. Investors should track whether these markets continue to offset Canadian pricing pressure and whether Safari and Leuna provide enough compliant supply to support that demand.

8. German Regulatory Changes and Transaction Approvals

German rules around telemedicine prescriptions, mail-order distribution, pharmacy dispensing, advertising and reimbursement affect the standalone business. A formal combination would also require analysis of the relevant corporate, securities and competition approvals across the parties’ jurisdictions; Curaleaf has not yet disclosed the complete approval package.

9. Leuna Facility Upgrade Completion

Aurora expects the Leuna expansion to be completed in the first half of fiscal 2027 and, together with proprietary cultivars, to double the site’s annual flower output. Completion, timing, remaining capex and production ramp remain relevant whether Aurora stays independent or becomes part of Curaleaf.

10. ATM Usage, Share Count and Free Cash Flow

The US$100 million ATM remains a permanent watch item, and Curaleaf specifically identifies equity issuance or other defensive capital actions as a circumstance that could cause it not to launch. Separately, Aurora still needs to show that medical cannabis adjusted EBITDA can become durable free cash flow after reimbursement pressure, integration spending and capacity investment.

24 Bull Case

The strategic-process bull case is that Curaleaf files the offer on the announced terms, improves it after Aurora’s review, negotiates a friendlier structure or triggers credible competing interest. Even without a higher bid, public interest from a scaled international operator validates that Aurora’s EU-GMP capacity and medical distribution footprint have strategic value. None of those outcomes is guaranteed.

The bull case for Aurora is that the company has already made the painful strategic pivot that many cannabis peers still need to make.

Aurora is focused on medical cannabis, not low-margin recreational volume. It has a strong international footprint, especially in Germany and Poland. It has EU-GMP infrastructure, a German production base, Australian and New Zealand exposure, a medical brand portfolio, genetics work, and a balance sheet with substantial cash and no conventional debt at fiscal year-end. It has also deconsolidated Bevo and is winding down lower-margin Canadian consumer cannabis, simplifying the business around the highest-return opportunity.

If FY2027 is only a reset year and not the start of a new deterioration cycle, Aurora could emerge cleaner. In that scenario, Germany and Poland keep growing, Safari adds needed EU-GMP capacity, Leuna expansion improves European output, medical gross margins remain strong enough, and adjusted EBITDA begins converting into positive free cash flow again.

The market capitalization remains modest relative to the company’s medical cannabis revenue base and cash position, which is why the stock can move sharply when sentiment improves. But the bull case requires execution, not just sector optimism.

25 Bear Case

The strategic-process bear case is that Curaleaf never commences the bid, withdraws under one of its pre-launch reservations or sees its own share price fall enough to reduce the value of the 0.3463-share component. The US$5.00 cap limits upside from a stronger Curaleaf price, while no minimum-value floor was disclosed. A failed process would return the market’s focus to Aurora’s FY2027 reset, cash conversion and dilution history.

The bear case is that Aurora’s medical cannabis reset may not be as durable as it appears.

Q4 FY2026 already showed margin pressure, lower adjusted EBITDA, weaker free cash flow and higher adjusted SG&A. FY2027 guidance calls for lower total net revenue and lower adjusted EBITDA because of reimbursed pricing changes. Germany may tighten access rules. Australia is competitive enough that Aurora recorded an impairment charge. Consumer cannabis wind-down may create further costs. Safari integration may take longer than expected. The ATM program may dilute shareholders if the company decides it needs more capital for capacity or M&A.

The deeper bear argument is that medical cannabis may still behave like a competitive commodity business over time, even in regulated markets. If price compression spreads from consumer cannabis into medical markets, the margin advantage may narrow. If reimbursement systems become more restrictive, revenue growth may slow. If Aurora cannot turn adjusted EBITDA into free cash flow, the valuation discount may persist.

The bear case does not require Aurora to fail. It only requires the company to remain “better than before, but not good enough” for the market to re-rate the stock.

26 Red Flags

Q4 EBITDA decline
C$9.2M
Adjusted EBITDA fell 50% sequentially from Q3 FY2026.
FY2027 reset
Lower EBITDA expected
Management guided lower annual adjusted EBITDA versus FY2026.
Free cash flow
Negative C$14.3M
Full-year FY2026 free cash flow remained negative.
ATM program
Up to US$100M
Useful funding tool, but also a dilution risk.

• No formal bid yet: Curaleaf has announced an intention and reserved circumstances in which it may decide not to proceed.
• Floating stock consideration: most of the stated US$4.00 value depends on Curaleaf shares, with no disclosed minimum-value floor.
• Asymmetric cap: the package is capped at US$5.00 if Curaleaf rises, while the announcement does not provide equivalent downside protection if it falls.
• Conditions still incomplete: the full regulatory, tender and closing conditions will only be known from the formal circular.
• Internal control material weakness: FY2026 audit included an adverse opinion on internal control over financial reporting.
• Regulatory exposure: Germany, Canada, Australia and other medical markets can change rules, reimbursement, distribution models and pricing frameworks.
• Sector sentiment: Cannabis remains a heavily damaged equity sector. Even improved execution can be ignored for long periods if cannabis sentiment stays weak.

27 Green Flags

Medical cannabis revenue
C$288.6M
Record FY2026 global medical cannabis net revenue.
Medical margin
68%
FY2026 adjusted gross margin before fair value adjustments.
International medical revenue
C$176.5M
Strong growth versus C$137.0M in FY2025.
Balance sheet
C$149.1M
Cash, cash equivalents and short-term investments at June 30, 2026; no debt.

• Strategic value recognized: Curaleaf’s public approach confirms that a scaled operator sees value in Aurora’s medical franchise and EU-GMP capacity.
• Headline premium: the stated US$4.00 implied value is 45% above the 30-day VWAP cited by Curaleaf.
• No financing or diligence condition proposed: Curaleaf says a formal bid would not depend on financing or due diligence, although other conditions remain undisclosed.
• Clear strategic focus: Aurora is exiting lower-margin Canadian consumer cannabis and focusing on global medical cannabis.
• EU-GMP capacity expansion: Safari’s 59,000 square foot Ontario facility received a three-year EU-GMP certification in July 2026, while Leuna upgrades are expected to increase German output.
• Genetics and IP: Aurora is developing proprietary cultivars and disease-resistant genetics that may support future cost and quality advantages.

28 Scenario Framework

Takeover-process overlay

• Offer proceeds on announced terms: value remains US$0.75 cash plus 0.3463 Curaleaf shares, subject to the US$5.00 cap and final conditions.
• Terms improve or an alternative emerges: Aurora’s committee negotiates a higher price, different mix or plan of arrangement, or another party enters. This is possible but not confirmed.
• Offer lapses: the bid fails its minimum tender condition or is withdrawn before December 1, leaving ACB to trade primarily on standalone execution and whatever strategic information the process revealed.

No probability-weighted merger-arbitrage conclusion is presented at this stage because the formal bid documents, complete conditions and a stable timestamped value for the Curaleaf share component are not yet available.

Bull Scenario: Medical Cannabis Platform Gets Re-Rated

In the bullish scenario, FY2027 proves to be a temporary reset. Canadian reimbursement pressure is absorbed, international growth remains strong, Germany and Poland continue expanding, Safari converts its three-year EU-GMP certification into real export volume, Leuna upgrades support European output, and medical cannabis gross margins stabilize in the mid-to-high fifties or better.

Aurora returns to positive free cash flow, uses the ATM sparingly or not at all, and investors begin valuing the company as a regulated medical cannabis platform rather than a failed Canadian cannabis relic.

Base Scenario: Cleaner Business, Still Discounted

In the base scenario, Aurora remains operationally credible but does not force a major re-rating. FY2027 revenue declines as guided, adjusted EBITDA falls, margins compress but remain respectable, and international growth offsets only part of the Canadian pressure. The balance sheet remains strong, but free cash flow recovery takes time.

The stock remains volatile and catalyst-driven, with investors waiting for evidence that FY2028 can restart growth.

Bear Scenario: Medical Margins Compress Faster Than Expected

In the bearish scenario, Canadian reimbursement pressure is worse than expected, Germany slows or tightens rules, Australia remains highly competitive, Safari integration does not deliver enough benefit, and medical margins trend lower. Free cash flow remains weak and the ATM becomes more relevant.

The market concludes that Aurora is cleaner than before but still trapped in the cannabis-sector valuation penalty.

29 Bottom Line

Curaleaf’s August 11 proposal changes the short-term ACB story, but it does not complete it. The economically correct description is US$0.75 cash plus 0.3463 Curaleaf shares, with a stated US$4.00 implied value at announcement, a US$5.00 cap and no disclosed minimum-value floor. No formal bid has been commenced, the 105-day clock has not started and Aurora’s board has not recommended acceptance or rejection.

The next evidence is documentary: Curaleaf’s formal circular, complete conditions and cap mechanics; Aurora’s independent special committee and recommendation; and any negotiation, higher proposal or alternative. Until then, ACB is an event-driven watch item layered on top of the same standalone Q1 FY2027 business.

Aurora Cannabis is no longer the same story that defined the old cannabis bubble.

The company has become a focused global medical cannabis operator with meaningful revenue, strong medical gross margins, international growth, EU-GMP infrastructure, a better balance sheet, and a clearer strategic identity. The FY2026 results prove that the medical cannabis platform is real.

But the stock is not a simple recovery story. Q4 FY2026 was weaker than the full-year headline. FY2027 guidance signals a reset. Free cash flow was negative for the year. The company still carries dilution risk, regulatory risk, internal-control remediation risk, and the heavy burden of cannabis-sector skepticism.

The cleanest way to frame $ACB is this: Aurora is not waiting for a U.S. legalization miracle. It is trying to build a regulated global medical cannabis export and manufacturing engine. Safari’s three-year EU-GMP certification makes that infrastructure thesis more credible. It does not settle the valuation debate because the company still has to convert certified capacity into profitable volume and cash.

Q1 supplied mixed proof: international medical growth remained strong, but adjusted margins, adjusted EBITDA and cash conversion weakened. The next test is Q2. If sequential revenue and adjusted EBITDA improve as management expects, Aurora may deserve renewed attention; if margins and cash conversion remain weak, the market may continue treating ACB as a cleaner company trapped inside the cannabis-sector discount.

The block below is a snapshot of the Stocktwits flow, with its date. These are opinions of retail traders and non-professional investors, not analyst research, and they measure attention and how one-sided positioning has become rather than anything about the business.

30 Primary Source Base

• Aurora Cannabis, “Aurora Cannabis corrects inaccurate statements made in support of Curaleaf Holdings’ hostile bid”, August 24, 2026: the point-by-point rebuttal, the under-10-per-cent German reimbursement volume, the 17 per cent international net revenue growth in fiscal Q1 2027, the Poland share claim, the more-than-40-per-cent five-year EU-GMP capacity increase, and the renewed instruction to take no action.
• Curaleaf announcement of its intention to launch an unsolicited take-over bid, August 11, 2026: 0.3463 Curaleaf shares plus US$0.75 cash per ACB share, stated US$4.00 implied value, US$5.00 cap, proposed 105-day acceptance period, no financing or due-diligence condition, pre-launch reservations and bidder synergy claims.
• Aurora response to Curaleaf’s proposal, August 11, 2026: prior-letter history, dispute over engagement, board intention to form an independent special committee, no decision and no action required from shareholders.
• Aurora 2026 AGM final voting results filed August 10, 2026
• Aurora Cannabis fiscal 2027 first quarter results, August 5, 2026: net revenue of C$67.6 million, medical C$64.0 million with Canadian medical down 25% and international up 17%, consumer C$2.1 million, adjusted gross margin before fair-value adjustments of 58%, adjusted SG&A of C$35.1 million, net loss from continuing operations of C$4.0 million, adjusted EBITDA of C$3.4 million, free cash flow outflow of C$5.8 million, cash and short-term investments of C$149.1 million with no debt, and the unchanged fiscal 2027 outlook.
• Aurora Cannabis Q1 FY2027 results and conference-call schedule, July 22, 2026
• Safari Flower Company three-year EU-GMP certification, July 23, 2026
• ISS support for Aurora’s 2026 AGM resolutions, July 27, 2026
• Aurora 2026 Management Information Circular and AGM materials
• Aurora Cannabis FY2026 Q4 and full-year results, June 11, 2026
• Aurora Cannabis FY2026 Form 40-F
• Aurora Cannabis FY2026 MD&A
• Aurora Cannabis FY2026 Annual Information Form
• Aurora Cannabis FY2026 audited consolidated financial statements

All financial figures are reported in Canadian dollars unless otherwise stated. Non-GAAP and adjusted metrics should be read together with the company’s reconciliations and definitions in its official filings.

This content is for informational and educational purposes only and does not constitute financial, investment, legal, tax or trading advice. It is not a recommendation to buy, sell or hold any security. Cannabis stocks are highly speculative and can be affected by regulatory changes, financing risk, liquidity, dilution, execution risk, pricing pressure, market sentiment and broader macro conditions. Every reader should verify primary filings, company releases, regulatory documents and market data before making any financial decision.